Fasting Supercharges Breast Cancer Treatment Through a Hidden Hormone Switch
A Nature study reveals fasting activates glucocorticoid receptors in breast tumors, dramatically boosting endocrine therapy and pointing to steroid drugs as a fasting substitute.
Summary
Researchers discovered that periodic fasting enhances tamoxifen efficacy in estrogen receptor-positive breast cancer by triggering a large-scale epigenetic shift that activates glucocorticoid receptor (GR) and progesterone receptor signaling inside tumors. Using mouse xenograft models, multiomics profiling, and clinical patient data, the team showed GR nuclear translocation is a key driver of fasting's anti-tumor effect. Crucially, administering exogenous GR ligands (corticosteroids) replicated fasting's tumor-suppressing benefits without requiring dietary restriction. Patients on a fasting-mimicking diet showed elevated blood cortisol and progesterone, and their tumor biopsies confirmed GR activation correlated inversely with proliferation markers—bridging animal findings to human biology.
Detailed Summary
Hormone receptor-positive (HR+) breast cancer represents approximately 75% of all breast cancer cases, and endocrine therapies like tamoxifen remain the treatment cornerstone. However, resistance—both primary and acquired—limits long-term outcomes. Prior animal research established that periodic fasting amplifies endocrine therapy efficacy, but the biological mechanism was unknown, and prolonged dietary restriction during multi-year endocrine regimens is impractical for most patients.
To unravel the mechanism, researchers xenografted human MCF7 HR+ breast cancer cells into athymic nude mice and administered weekly 48-hour fasting cycles combined with tamoxifen over four weeks. Tumors were then subjected to comprehensive multiomics analysis: transcriptomics, proteomics, immunohistochemistry, and ChIP-seq profiling of the active enhancer/promoter mark H3K27ac alongside multiple transcription factors. This revealed that fasting combined with tamoxifen induced profound epigenomic reprogramming compared to either intervention alone, with two major opposing changes: loss of activator protein-1 (AP-1) family enhancer activity (AP-1 members FOSL2, JUN, FOSL1, FOS, JUND—known breast cancer growth promoters) and gain of steroid hormone receptor binding, particularly glucocorticoid receptor (GR) and progesterone receptor (PR) activity.
Immunohistochemistry confirmed that fasting—alone or with tamoxifen—dramatically increased nuclear GR localization, a hallmark of GR activation, without affecting ERα or PR protein levels or localization. Experimental GR and PR ChIP-seq validated their increased chromatin binding at fasting-induced H3K27ac sites. Gene expression analyses showed upregulation of GR target genes, and GR knockout experiments in mouse models significantly blunted the anti-tumor effect of fasting combined with tamoxifen, establishing GR as mechanistically essential rather than correlative.
Critically, the team demonstrated that exogenous GR ligand administration (corticosteroids) could replicate the tumor-suppressive and tamoxifen-enhancing effects of fasting without requiring food restriction, promoting measurable tumor regression. In a clinical cohort of patients undergoing a cyclic fasting-mimicking diet, blood cortisol and progesterone levels rose significantly. Post-FMD tumor biopsies showed GR activation markers inversely correlated with Ki-67 and other proliferation markers, providing direct human confirmation of the preclinical mechanism.
These findings reframe how fasting interacts with cancer biology: rather than simply starving tumors of nutrients, fasting orchestrates a systemic hormonal stress response that reshapes the tumor epigenome through GR, converting a broadly expressed receptor into a tumor suppressor in the HR+ breast cancer context. The results open a clinically actionable path—evaluating corticosteroid adjuvants to standard endocrine therapy—potentially offering fasting's benefits to patients who cannot safely or practically undertake dietary restriction.
Key Findings
- Fasting combined with tamoxifen induces massive epigenetic reprogramming in HR+ breast cancer xenografts, activating GR and PR signaling.
- AP-1 family enhancer activity is sharply reduced by fasting, suppressing a known breast cancer proliferation pathway.
- GR knockout in mouse models significantly impairs the anti-tumor effect of fasting plus tamoxifen, proving GR is mechanistically essential.
- Exogenous corticosteroid administration mimics fasting's tumor-suppressive enhancement of tamoxifen without dietary restriction.
- Patients on a fasting-mimicking diet show elevated cortisol and progesterone, and GR activation in tumor biopsies inversely correlates with proliferation markers.
Methodology
Mouse xenograft experiments used athymic nude mice implanted with MCF7 HR+ breast cancer cells, subjected to 48-hour weekly fasting cycles with or without tamoxifen for four weeks. Tumors underwent multiomics profiling including H3K27ac ChIP-seq, transcriptomics, proteomics, and immunohistochemistry; GR knockout models confirmed causal role. Clinical validation used patient tumor biopsies and blood samples from a cyclic fasting-mimicking diet trial.
Study Limitations
Xenograft models used immunocompromised mice lacking a full immune system, which may not fully capture fasting's effects in immunocompetent hosts. The clinical cohort validating GR activation was relatively small, and causal efficacy data from randomized human trials with corticosteroid adjuvants are still lacking. Long-term safety of corticosteroid co-administration with endocrine therapy remains to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.